Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101 Jul 17, 2017
Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics Jul 03, 2017
Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies Jun 05, 2017
Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon Jun 01, 2017
Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol May 19, 2017
